U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021
The U.S. insomnia market is projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021.
In 2016, the cognitive behavioural therapy for insomnia (CBTI) segment is expected to account for the largest share of the market. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.
In 2016, the prescription sleep aids segment is expected to account for the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market. In 2016, the zolpidem segment is expected to account for the largest share of the non-benzodaizepines prescription sleep aids market. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market.
The over-the-counter sleep aids segment of the U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. In 2016, the antihistamines sleep aids segment is expected to hold the largest share of the over-the-counter sleep aids market, whereas, melatonin is expected to grow at the highest CAGR during the forecast period. Growing awareness about the advantages of melatonin such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.
Some of the key players offering insomnia treatment (pharmacological) include Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).
Research Coverage
The market study covers the U.S. insomnia market, by type of treatment, to estimate the overall market size during 2013 to 2021. This report also covers the drivers, restraints, and opportunities of the market along with the competitive landscape of the U.S. insomnia market players.
Reasons to buy this report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
In 2016, the cognitive behavioural therapy for insomnia (CBTI) segment is expected to account for the largest share of the market. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.
In 2016, the prescription sleep aids segment is expected to account for the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market. In 2016, the zolpidem segment is expected to account for the largest share of the non-benzodaizepines prescription sleep aids market. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market.
The over-the-counter sleep aids segment of the U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. In 2016, the antihistamines sleep aids segment is expected to hold the largest share of the over-the-counter sleep aids market, whereas, melatonin is expected to grow at the highest CAGR during the forecast period. Growing awareness about the advantages of melatonin such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.
Some of the key players offering insomnia treatment (pharmacological) include Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).
Research Coverage
The market study covers the U.S. insomnia market, by type of treatment, to estimate the overall market size during 2013 to 2021. This report also covers the drivers, restraints, and opportunities of the market along with the competitive landscape of the U.S. insomnia market players.
Reasons to buy this report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information regarding products and services offered by the top players in the U.S. insomnia market
- Product Development/Innovation: Detailed insights on research & development activities, and new product launches in the U.S. insomnia market
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the U.S. insomnia market
- Competitive Assessment: In-depth assessment of strategies, products, and pipeline products of the key players in the U.S. insomnia market
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 KEY STAKEHOLDERS/INFLUENCERS
2. RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION – NON-PHARMACOLOGICAL TREATMENTS MARKET
2.1.1 MARKET BREAKDOWN AND DATA TRIANGULATION
2.1.2 KEY DATA FROM SECONDARY SOURCES
2.1.3 KEY DATA FROM PRIMARY SOURCES
2.2 MARKET SIZE ESTIMATION – PHARMACOLOGICAL TREATMENTS MARKET
2.2.1 MARKET FORECAST MODEL
2.2.2 MARKET SIZE ESTIMATION
2.2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.2.4 KEY DATA FROM PRIMARY AND SECONDARY SOURCES
2.3 RESEARCH ASSUMPTIONS
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
4.1 PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
4.2 AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
4.3 LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
4.4 U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA
5. MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.3 GOVERNMENT SUPPORT TO CONTROL RISING INSOMNIA COST
5.2.1.4 OTC SLEEP AIDS TO DRIVE THE PHARMACOLOGICAL TREATMENT MARKET GROWTH
5.2.2 MARKET RESTRAINTS
5.2.2.1 EROSION IN BRANDED PRESCRIPTION SLEEP AID SALES DUE TO GROWING ADOPTION OF GENERICS
5.2.2.2 SIDE EFFECTS OF BENZODIAZEPINE AND NON-BENZODIAZEPINE DRUGS
5.2.2.3 NON PHARMACOLOGICAL THERAPIES TO RESTRICT THE GROWTH OF DRUGS MARKET
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 UNMET NEED FOR MORE EFFECTIVE AND SAFE DRUGS
5.2.3.2 PRESENCE OF LARGE INSOMNIA POPULATION POOL
6. NON-PHARMACOLOGICAL TREATMENT MARKET
6.1 INTRODUCTION
6.1.1 COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
6.1.2 HYPNOTHERAPY
6.1.3 OTHER ALTERNATIVE THERAPIES
6.2 THERAPY RECOMMENDATION, 2015 (%)
6.3 QUALITATIVE ASSESSMENT
7. PHARMACOLOGICAL TREATMENT MARKET
7.1 INTRODUCTION
7.2 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TYPE
7.2.1 U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA
7.2.1.1 U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
7.2.1.1.1 U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
7.2.2 U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
8 . COMPETITIVE LANDSCAPE
8.1 KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET
8.2 TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA
8.3 CORPORATE STRATEGIES FOLLOWED WITHIN U.S. INSOMNIA MARKET
8.4 COMPETITIVE SITUATIONS & TRENDS
8.4.1 PRODUCT LAUNCHES & APPROVALS
8.4.2 COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS
8.4.3 ACQUISITIONS
9. COMPANY PROFILES
9.1 INTRODUCTION
9.2 MERCK & CO., INC.
9.3 EISAI CO., LTD.
9.4 MEDA CONSUMER HEALTHCARE, INC
9.5 TAKEDA PHARMACEUTICALS COMPANY LTD.
9.6 PFIZER INC.
9.7 SANOFI
9.8 VANDA PHARMACEUTICALS
9.9 PERNIX THERAPEUTICS
9.10 PURDUE PHARMACEUTICALS L.P.
10. APPENDIX
10.1 DISCUSSION GUIDE
10.2 RELATED REPORTS
10.3 RELATED REPORTS
10.4 KNOWLEDGESTORE SUBSCRIPTION PORTAL
10.5 MNM KNOWLEDGESTORE: SNAPSHOT
10.6 RT: REAL-TIME MARKET INTELLIGENCE
10.7 DISCLAIMER
10.8 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 KEY STAKEHOLDERS/INFLUENCERS
2. RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION – NON-PHARMACOLOGICAL TREATMENTS MARKET
2.1.1 MARKET BREAKDOWN AND DATA TRIANGULATION
2.1.2 KEY DATA FROM SECONDARY SOURCES
2.1.3 KEY DATA FROM PRIMARY SOURCES
2.2 MARKET SIZE ESTIMATION – PHARMACOLOGICAL TREATMENTS MARKET
2.2.1 MARKET FORECAST MODEL
2.2.2 MARKET SIZE ESTIMATION
2.2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.2.4 KEY DATA FROM PRIMARY AND SECONDARY SOURCES
2.3 RESEARCH ASSUMPTIONS
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
4.1 PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
4.2 AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
4.3 LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
4.4 U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA
5. MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.3 GOVERNMENT SUPPORT TO CONTROL RISING INSOMNIA COST
5.2.1.4 OTC SLEEP AIDS TO DRIVE THE PHARMACOLOGICAL TREATMENT MARKET GROWTH
5.2.2 MARKET RESTRAINTS
5.2.2.1 EROSION IN BRANDED PRESCRIPTION SLEEP AID SALES DUE TO GROWING ADOPTION OF GENERICS
5.2.2.2 SIDE EFFECTS OF BENZODIAZEPINE AND NON-BENZODIAZEPINE DRUGS
5.2.2.3 NON PHARMACOLOGICAL THERAPIES TO RESTRICT THE GROWTH OF DRUGS MARKET
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 UNMET NEED FOR MORE EFFECTIVE AND SAFE DRUGS
5.2.3.2 PRESENCE OF LARGE INSOMNIA POPULATION POOL
6. NON-PHARMACOLOGICAL TREATMENT MARKET
6.1 INTRODUCTION
6.1.1 COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
6.1.2 HYPNOTHERAPY
6.1.3 OTHER ALTERNATIVE THERAPIES
6.2 THERAPY RECOMMENDATION, 2015 (%)
6.3 QUALITATIVE ASSESSMENT
7. PHARMACOLOGICAL TREATMENT MARKET
7.1 INTRODUCTION
7.2 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TYPE
7.2.1 U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA
7.2.1.1 U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
7.2.1.1.1 U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
7.2.2 U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
8 . COMPETITIVE LANDSCAPE
8.1 KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET
8.2 TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA
8.3 CORPORATE STRATEGIES FOLLOWED WITHIN U.S. INSOMNIA MARKET
8.4 COMPETITIVE SITUATIONS & TRENDS
8.4.1 PRODUCT LAUNCHES & APPROVALS
8.4.2 COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS
8.4.3 ACQUISITIONS
9. COMPANY PROFILES
9.1 INTRODUCTION
9.2 MERCK & CO., INC.
9.3 EISAI CO., LTD.
9.4 MEDA CONSUMER HEALTHCARE, INC
9.5 TAKEDA PHARMACEUTICALS COMPANY LTD.
9.6 PFIZER INC.
9.7 SANOFI
9.8 VANDA PHARMACEUTICALS
9.9 PERNIX THERAPEUTICS
9.10 PURDUE PHARMACEUTICALS L.P.
10. APPENDIX
10.1 DISCUSSION GUIDE
10.2 RELATED REPORTS
10.3 RELATED REPORTS
10.4 KNOWLEDGESTORE SUBSCRIPTION PORTAL
10.5 MNM KNOWLEDGESTORE: SNAPSHOT
10.6 RT: REAL-TIME MARKET INTELLIGENCE
10.7 DISCLAIMER
10.8 AUTHOR DETAILS
LIST OF TABLES
Table 1 KEY STAKEHOLDERS/INFLUENCERS FOR DIAGNOSED INSOMNIA PATIENTS
Table 2 PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
Table 3 AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
Table 4 LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
Table 5 INSOMNIA TREATMENT SELECTION CRITERIA: IMPACT ANALYSIS
Table 6 U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT (QUALITATIVE ASSESSMENT)
Table 7 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY TYPE, 2013-2021 (USD MILLION)
Table 8 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY PRESCRIPTION SLEEP AIDS, 2013-2021 (USD MILLION)
Table 9 U.S.: PRESCRIPTIONS SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
Table 10 U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
Table 11 U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
Table 12 KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET (2016)
Table 13 TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA (2016)
Table 14 PRODUCT LAUNCHES AND APPROVALS, 2013 –2016
Table 15 COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS 2013–2016
Table 16 ACQUISITIONS, 2013–2016
Table 1 KEY STAKEHOLDERS/INFLUENCERS FOR DIAGNOSED INSOMNIA PATIENTS
Table 2 PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
Table 3 AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
Table 4 LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
Table 5 INSOMNIA TREATMENT SELECTION CRITERIA: IMPACT ANALYSIS
Table 6 U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT (QUALITATIVE ASSESSMENT)
Table 7 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY TYPE, 2013-2021 (USD MILLION)
Table 8 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY PRESCRIPTION SLEEP AIDS, 2013-2021 (USD MILLION)
Table 9 U.S.: PRESCRIPTIONS SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
Table 10 U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
Table 11 U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
Table 12 KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET (2016)
Table 13 TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA (2016)
Table 14 PRODUCT LAUNCHES AND APPROVALS, 2013 –2016
Table 15 COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS 2013–2016
Table 16 ACQUISITIONS, 2013–2016
LIST OF FIGURES
Figure 1 SEGMENTATION & COVERAGE
Figure 2 PREVALENCE OF INSOMNIA, BY TYPE (2012-2015)
Figure 3 RESEARCH DESIGN – NON-PHARMACOLOGICAL TREATMENTS MARKET
Figure 4 MARKET BREAKDOWN AND DATA TRIANGULATION – NON-PHARMACOLOGICAL TREATMENTS MARKET
Figure 5 FORECASTING MODEL– PHARMACOLOGICAL TREATMENTS MARKET
Figure 6 MARKET SIZE ESTIMATION – PHARMACOLOGICAL TREATMENTS MARKET
Figure 7 MARKET BREAKDOWN AND DATA TRIANGULATION – PHARMACOLOGICAL TREATMENTS MARKET
Figure 8 ASSUMPTIONS FOR THE STUDY
Figure 9 U.S. INSOMNIA MARKET SCOPE
Figure 10 PHARMACOLOGICAL TREATMENT MARKET SHARE, BY TYPE (2014-2021)
Figure 11 U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA
Figure 12 U.S. INSOMNIA MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Figure 13 U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT, THERAPY RECOMMENDATION, 2015 (%)
Figure 14 U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION
Figure 15 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, 2013-2021 (USD MILLION)
Figure 16 MARKET SHARE: PHARMACOLOGICAL TREATMENT MARKET (2016)
Figure 17 MARKET SHARE: PRESCRIPTION SLEEP AIDS MARKET (2016)
Figure 18 U.S. INSOMNIA PRESCRIPTION SLEEP AIDS MARKET SNAPSHOT
Figure 19 MARKET SHARE: NON-BENZODIAZEPINE SLEEP AIDS MARKET (2016)
Figure 20 MARKET SHARE: NON-BENZODIAZEPINE SLEEP AIDS MARKET (2016)
Figure 21 U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SNAPSHOT
Figure 22 BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES AND APPROVALS—KEY STRATEGIES ADOPTED BY MARKET PLAYERS (2013-2016)
Figure 23 GEOGRAPHIC REVENUE MIX OF MAJOR PLAYERS IN THE U.S. INSOMNIA MARKET (2016)
Figure 24 SUMITOMO DAINIPPON PHARMA CO., LTD.: COMPANY SNAPSHOT (2015)
Figure 25 SANOFI: COMPANY SNAPSHOT (2015)
Figure 26 PFIZER INC: COMPANY SNAPSHOT (2015)
Figure 27 TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT (2015)
Figure 28 MERCK & CO., INC.: COMPANY SNAPSHOT (2015)
Figure 29 MEDA CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT (2015)
Figure 30 EISAI CO., LTD.: COMPANY SNAPSHOT (2015)
Figure 31 PURDUE PHARMACEUTICALS L.P.: COMPANY SNAPSHOT (2015)
Figure 32 PERNIX THERAPEUTICS: COMPANY SNAPSHOT (2015)
Figure 33 VANDA PHARMACEUTICALS: COMPANY SNAPSHOT (2015)
Figure 1 SEGMENTATION & COVERAGE
Figure 2 PREVALENCE OF INSOMNIA, BY TYPE (2012-2015)
Figure 3 RESEARCH DESIGN – NON-PHARMACOLOGICAL TREATMENTS MARKET
Figure 4 MARKET BREAKDOWN AND DATA TRIANGULATION – NON-PHARMACOLOGICAL TREATMENTS MARKET
Figure 5 FORECASTING MODEL– PHARMACOLOGICAL TREATMENTS MARKET
Figure 6 MARKET SIZE ESTIMATION – PHARMACOLOGICAL TREATMENTS MARKET
Figure 7 MARKET BREAKDOWN AND DATA TRIANGULATION – PHARMACOLOGICAL TREATMENTS MARKET
Figure 8 ASSUMPTIONS FOR THE STUDY
Figure 9 U.S. INSOMNIA MARKET SCOPE
Figure 10 PHARMACOLOGICAL TREATMENT MARKET SHARE, BY TYPE (2014-2021)
Figure 11 U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA
Figure 12 U.S. INSOMNIA MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Figure 13 U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT, THERAPY RECOMMENDATION, 2015 (%)
Figure 14 U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION
Figure 15 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, 2013-2021 (USD MILLION)
Figure 16 MARKET SHARE: PHARMACOLOGICAL TREATMENT MARKET (2016)
Figure 17 MARKET SHARE: PRESCRIPTION SLEEP AIDS MARKET (2016)
Figure 18 U.S. INSOMNIA PRESCRIPTION SLEEP AIDS MARKET SNAPSHOT
Figure 19 MARKET SHARE: NON-BENZODIAZEPINE SLEEP AIDS MARKET (2016)
Figure 20 MARKET SHARE: NON-BENZODIAZEPINE SLEEP AIDS MARKET (2016)
Figure 21 U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SNAPSHOT
Figure 22 BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES AND APPROVALS—KEY STRATEGIES ADOPTED BY MARKET PLAYERS (2013-2016)
Figure 23 GEOGRAPHIC REVENUE MIX OF MAJOR PLAYERS IN THE U.S. INSOMNIA MARKET (2016)
Figure 24 SUMITOMO DAINIPPON PHARMA CO., LTD.: COMPANY SNAPSHOT (2015)
Figure 25 SANOFI: COMPANY SNAPSHOT (2015)
Figure 26 PFIZER INC: COMPANY SNAPSHOT (2015)
Figure 27 TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT (2015)
Figure 28 MERCK & CO., INC.: COMPANY SNAPSHOT (2015)
Figure 29 MEDA CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT (2015)
Figure 30 EISAI CO., LTD.: COMPANY SNAPSHOT (2015)
Figure 31 PURDUE PHARMACEUTICALS L.P.: COMPANY SNAPSHOT (2015)
Figure 32 PERNIX THERAPEUTICS: COMPANY SNAPSHOT (2015)
Figure 33 VANDA PHARMACEUTICALS: COMPANY SNAPSHOT (2015)
